Lymphomas are hematologic malignancies, specifically of the lymphatic system. They are classified into two types: Hodgkin and non-Hodgkin (NHL). NHL is the seventh most common cancer in the United States and Hodgkin seen much less frequently as the 26th, but new treatment options have improved survival rates.
Zanubrutinib (BrukinsaTM) received U.S. Food and Drug Administration accelerated approval on November 14, 2019, for the treatment of adult patients with mantle cell lymphoma who have received at least one prior therapy.
Over the past three years, Sharon, age 38, has been intermittently receiving treatment for ovarian cancer. She was initially treated with carboplatin and paclitaxel and remained in remission for 20 months. She responded well to second-line therapy (carboplatin, gemcitabine, and bevacizumab), remaining on bevacizumab maintenance until she experienced a relapse eight months later.
In February 2019, my colleagues and I published a retrospective analysis of patient-reported satisfaction comparing those who had contact with an oncology nurse navigator (ONN) and those who did not. We analyzed surveys from patients with outpatient oncology infusion or radiation oncology visits in a 24-month period. First, we sorted the surveys into two groups—self-reported ONN contact (n = 315) and self-reported no contact with an ONN (n = 172)—and compared satisfaction.